Related Experiment Video
Updated: Jan 18, 2026

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
Published on: July 9, 2020
Integrin αvβ3 Antagonist Ameliorates Atherosclerotic Progression by Reducing Platelet Hyperactivation
Mengyun Xu1, Xurui Zhang1, Feng Qi1
1Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China.
Platelet hyperactivation in atherosclerosis is linked to increased integrin αvβ3 and Multimerin 1 (MMRN1). Targeting this axis reduced platelet activity and disease severity in mice, offering a potential therapeutic strategy.
Area of Science:
- Cardiovascular Biology
- Hematology
- Molecular Medicine
Background:
- Platelet hyperactivation is a key risk factor for atherosclerotic cardiovascular diseases.
- Integrin αvβ3 and Multimerin 1 (MMRN1) roles in platelet function during atherosclerosis are not fully understood.
Purpose of the Study:
- To investigate the expression and function of integrin αvβ3 and MMRN1 in platelets from atherosclerotic patients.
- To evaluate the therapeutic potential of targeting the αvβ3/MMRN1 axis in atherosclerosis.
Main Methods:
- Examined αvβ3 and MMRN1 expression in platelets from healthy controls, coronary heart disease (CHD), and acute myocardial infarction (AMI) patients using qRT-PCR and ELISA.
- Analyzed correlations between αvβ3/MMRN1 levels, platelet counts, and aggregation.
- Utilized a mouse atherosclerosis model to assess the effects of an αvβ3 antagonist and MMRN1 knockdown.
Main Results:
- Found positive correlations between MMRN1 and αvβ3 expression levels with platelet counts and aggregation.
- Observed that αvβ3 antagonist treatment reduced elevated platelet counts and aggregation in CHD and AMI patients.
- Demonstrated that αvβ3 antagonist treatment and MMRN1 knockdown ameliorated atherosclerosis severity in mice.
Conclusions:
- Upregulation of integrin αvβ3 and MMRN1 contributes to platelet hyperactivation in atherosclerotic vascular diseases.
- Targeting the αvβ3/MMRN1 axis represents a promising therapeutic strategy for managing atherosclerotic vascular diseases.
More Related Videos
10:57Using In Vivo and Tissue and Cell Explant Approaches to Study the Morphogenesis and Pathogenesis of the Embryonic and Perinatal Aorta
Published on: September 12, 2017
05:12Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice
Published on: August 13, 2015
Related Concept Videos
Atherosclerosis III: Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Intracellular Signaling Affects Focal Adhesions
Some...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...